GROWTH HORMONE AXIS RESEARCH
One Axis, Three Signals
A measured read of the published science behind CJC-1295/Ipamorelin, sermorelin, and tesamorelin — three different ways researchers have tried to raise the body's own growth-hormone pulse, and how far each result actually reaches.
CJC-1295 / Ipamorelin
A GHRH analogue and a selective ghrelin-receptor agonist, stacked on the theory that two independent signaling paths produce a bigger growth-hormone pulse than either alone — reasoned from separate single-agent studies, since the fixed combination itself has never been tested in a controlled human trial.
Read the research →
Sermorelin
The anchor of this desk. The shortest fragment of natural GHRH that still fully activates the pituitary — once an FDA-approved pediatric therapy, now studied for whether a feedback-preserving signal can support an aging or blunted growth-hormone axis.
Read the research →
Tesamorelin
The one compound here with current FDA approval and a genuine randomized-trial program behind it — for a specific, narrow indication, not general growth-hormone-axis support.
Read the research →The short version
LKN Peptide is a reading desk, not a supplier. It follows the published research on three peptides studied for one shared idea: nudging the body's own growth-hormone axis rather than replacing growth hormone directly. The growth-hormone axis is the signaling chain that runs from the brain to the pituitary gland to the liver — a hormone called GHRH tells pituitary cells to release growth hormone (GH), and GH then tells the liver to make a second hormone, IGF-1, which does much of the actual work in muscle, fat, and connective tissue.
All three peptides on this desk are built to act somewhere in that chain rather than skip it. CJC-1295/Ipamorelin combines two separate signals aimed at the pituitary. Sermorelin is the smallest working fragment of the brain's own GHRH hormone. Tesamorelin is a longer-lasting, chemically stabilized version of the same natural hormone, and the only one of the three with FDA approval. This page walks through what each compound was actually studied for, and how confidently that evidence reaches.
What is the growth hormone axis?
Growth hormone (GH) is made and released by the pituitary gland, a pea-sized structure at the base of the brain, in response to a hormone from the hypothalamus called growth hormone-releasing hormone (GHRH). Once released, GH travels to the liver, where it triggers production of insulin-like growth factor-1 (IGF-1) — the hormone that carries out much of GH's downstream work in bone, muscle, and fat tissue. This entire chain — hypothalamus to pituitary to liver to tissue — is what researchers mean by the growth-hormone axis, and it is regulated by feedback: rising IGF-1 and a hormone called somatostatin both act to quiet the signal back down, keeping GH release naturally pulsed rather than constant.
The peptides on this desk are studied as GHRH analogues or growth-hormone secretagogues — compounds designed to stimulate that upstream signal rather than deliver GH itself. The reasoning is that acting upstream leaves the body's own feedback loop intact, which is mechanistically different from injecting exogenous growth hormone directly, though it does not automatically make every downstream effect risk-free [6].
Three ways researchers have tried to raise GH
The three peptides on this desk are not a dose-response ladder the way some other compound families are — they are three different design philosophies aimed at the same target.
CJC-1295/Ipamorelin combines a long-acting GHRH analogue with a selective ghrelin-receptor agonist, on the theory that two independent receptor pathways converging on the same pituitary cell produce a larger GH pulse than either one alone — a mechanism with genuine cell-level support [5], though the fixed combination itself has no dedicated human trial.
Sermorelin is the anchor of this desk: the shortest 29-amino-acid fragment of natural GHRH that still fully activates the receptor. It was FDA-approved for pediatric growth-hormone deficiency before that approval lapsed for commercial reasons, and it remains the most physiologic of the three because it works entirely through the body's own feedback-regulated release.
Tesamorelin is a chemically stabilized, longer-acting analogue of the full 44-amino-acid GHRH hormone. It is the only one of the three with a current FDA-approved indication and the deepest randomized-trial evidence base — though that approval covers a specific population, not general axis support. See the full comparison.
How this desk reads the evidence
Three things govern what appears on this site. First, every research claim traces to a numbered citation on the shared references page — peer-reviewed trials, structural biology papers, and clinical reviews, cited by number throughout. Second, the evidence is described at the strength it actually has: a phase and sample size are noted, and a single-cell-line receptor study is never presented with the same confidence as a multi-decade randomized trial. Third, this desk is honest that the three compounds are not evidenced equally. Tesamorelin carries the deepest randomized, placebo-controlled trial record of the three [1][14][16]. Sermorelin has real but older and smaller human trials plus a body of more recent editorial commentary urging caution about anti-aging claims [7][8]. CJC-1295/Ipamorelin has solid single-agent pharmacology for each half but no controlled trial of the combined product as it is actually used. None of this is medical advice, and no dose is recommended here — where a number appears, it is the dose a cited study used, not a suggestion.